Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Finally, Millennium Management LLC raised its holdings in shares of Daré Bioscience by 73.9% during the 2nd quarter.
HC Wainwright raised their price target on shares of Daré Bioscience from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, December 13th.
In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands.
INVO Bioscience has a 12-month low of $0.15 and a 12-month high of $1.65.
Source: https://www.dailypolitical.com/2023/07/01/invo-bioscience-inc-nasdaqinvo-short-interest-update.html
Jenny Whilde is an Adjunct Research Scientist in Marine Bioscience at the University of Florida.
On average, equities analysts forecast that Harvard Bioscience, Inc. will post 0.12 earnings per share for the current year.
Sell-side analysts predict that Aadi Bioscience, Inc. will post -2.53 EPS for the current year.
That compares to run-rate unit sales of Narcan of under 3 million to Emergent Bioscience.
Source: https://seekingalpha.com/article/4577506-whats-the-opiant-cvr-worth?source=feed_all_articles
The South Bay Workforce Investment Board (SBWIB) conducted a graduation ceremony on Dec. 12 for 28 Morningside High School seniors who have recently participated in the SBWIB’s Bioscience Pre-Apprenticeship Program.
Source: https://www.dailybreeze.com/2023/01/18/south-bay-workforce-agency-ramping-up-programs-in-new-year/
Vanguard Group Inc. raised its stake in Harvard Bioscience by 12.8% in the 1st quarter.
We are currently developing the platform for North American distribution around our rights to use Lexaria Bioscience Corp.’s ground-breaking DehydraTECH patent portfolio for product development, licensing and B2B sales of cannabis ingredients.
What’s more, birth controlis perceived to address a health condition “that is not life-threatening,” notes Sabrina Martucci Johnson, CEO of Daré Bioscience, a women’s health company developing a nonhormonal contraceptive for Bayer.